Skip to main content
SpringerLink
Log in

Erkrankungen des granulozytären/ monozytären Systems

  • Chapter
Medizinische Therapie 2007 | 2008

  • 80 Accesses

Auszug

Unter dem Begriff Leukämie werden heute verschiedene Erkrankungen zusammengefasst, die durch maligne Transformation hämatopoetischer Zellen entstehen. Gemeinsames Merkmal ist die Proliferation von Leukämiezellen im Knochenmark und ggf. in lympha-tischen Geweben sowie deren häufige Ausschwemmung ins periphere Blut. Die Symptome resultieren aus der Verdrängung und Unterdrückung der normalen Hämatopoese.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 29.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 39.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Bishop JF, Matthews JP, Young GA et al. (1996) A randomized study of highdose cytarabine in induction in acute myeloid leukemia. Blood 87(5): 1710–1717

    PubMed  CAS  Google Scholar 

  • Büchner T, Hiddemann W, Berdel We et al. (2003) 6-Thioguanine, cytarabine, and daunorubicin (TAD) and highdose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol 21(24): 4496–4504

    Article  PubMed  Google Scholar 

  • Buchner T, Berdel W, Schoch C et al. (2006) Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol. 24(16): 2480–2489.

    Article  PubMed  Google Scholar 

  • Cassileth PA, Harrington DP, Appelbaum FR et al. (1998) Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 339(23): 1649–1656

    Article  PubMed  CAS  Google Scholar 

  • Harousseau JL, Cahn JY, Pignon B et al. (1997) Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 90(8): 2978–2986

    PubMed  CAS  Google Scholar 

  • Schnittger S, Schoch C, Dugas M et al. (2002) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100(1): 59–66

    Article  PubMed  CAS  Google Scholar 

  • Lengfelder E, Reichert A, Schoch C et al. (2000) Double induction strategy including high dose cytarabine in combination with alltrans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia 14(8): 1362–1370

    Article  PubMed  CAS  Google Scholar 

  • Mayer RJ, Davis RB, Schiffer CA et al. (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331(14): 896–903

    Article  PubMed  CAS  Google Scholar 

  • Mrozek K, Bloomfield CD. (2006) Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology Am Soc Hematol Educ Program: 169–77

    Google Scholar 

  • Zittoun RA, Mandelli F, Willemze R et al. (1995) Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 332(4): 217–223

    Article  PubMed  CAS  Google Scholar 

Literatur

  • Bain BJ (2000) Hypereosinophilia. Curr Opin Hematol 7(1): 21–25

    Article  PubMed  CAS  Google Scholar 

  • Kim HS, Chun YS, Chang SN, Park WH (2001) Hypereosinophilic syndrome: correlation between clinical severity and cutaneous microthrombi. Int J Dermatol 40(5): 330–332

    Article  PubMed  CAS  Google Scholar 

  • Pardanani A, T Reeder, LF Porrata et al. (2003) Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 101(9): 3391–3397

    Article  PubMed  CAS  Google Scholar 

  • Pardanani A, Tefferi A (2004) Imatinib therapy for hypereosinophilic syndrome and eosinophiliaassociated myeloproliferative disorders. Leuk Res 28[Suppl 1]: 47–52

    Article  Google Scholar 

  • Robyn J (2006) Imatinib-responsive hypereosinophilic syndrome. Leuk Res 30(8): 915–6

    Article  PubMed  Google Scholar 

  • Tefferi A, Patnaik MM, Pardanani A (2006). Eosinophilia: secondary, clonal and idiopathic. Br J Haematol. 133(5): 468–92

    Article  PubMed  CAS  Google Scholar 

Literatur

  • Borges WG, Augustine NH, Hill HR (2000) Defective interleukin-12/interferongamma pathway in patients with hyperimmunoglobulinemia E syndrome. J Pediatr 136(2): 176–180

    Article  PubMed  CAS  Google Scholar 

  • Erlewyn-Lajeunesse MD (2000) Hyperimmunoglobulin-E syndrome with recurrent infection: a review of current opinion and treatment. Pediatr Allergy Immunol 11(3): 133–141

    Article  PubMed  CAS  Google Scholar 

  • Introne W, Boissy RE, Gahl WA (1999) Clinical, molecular, and cell biological aspects of Chediak-Higashi syndrome. Mol Genet Metab 68(2): 283–303

    Article  PubMed  CAS  Google Scholar 

  • Shemer A, Weiss G, Confino Y, Trau H (2001) The hyper-IgE syndrome. Two cases and review of the literature. Int J Dermatol 40(10): 622–628

    Article  PubMed  CAS  Google Scholar 

  • Ward DM, Griffiths GM, Stinchcombe JC, Kaplan J (2000) Analysis of the lysosomal storage disease Chediak-Higashi syndrome. Traffic 1(11): 816–822

    Article  PubMed  CAS  Google Scholar 

Literatur

  • Andres E, Kurtz JE, Martin-Hunyadi C, Kaltenbach G, Alt M; Weber JC, Sibilia J, Schlienger JL, Dufour P, Maloisel F (2002) Nonchemotherapy drug-induced agranulocytosis in elderly patients: the effects of granulocyte colony-stimulating factor. Am J Med 112(6): 460–4

    Article  PubMed  CAS  Google Scholar 

  • Beauchesne MF, Shalansky SJ (1999) Nonchemotherapy druginduced agranulocytosis: a review of 118 patients treated with colonystimulating factors. Pharmacotherapy 19(3): 299–305

    Article  PubMed  CAS  Google Scholar 

  • Leibovici L, Paul M, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A, Kern WV (2006) Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 107(8): 1743–51

    Article  PubMed  CAS  Google Scholar 

Literatur

  • Barranger JA, E O’Rourke (2001) Lessons learned from the development of enzyme therapy for Gaucher disease. J Inherit Metab Dis 24[Suppl 2]: 89–96

    Article  PubMed  CAS  Google Scholar 

  • Bohm P, Kunz W, Horny HP, Einsele H (2001) Adult Gaucher disease in association with primary malignant bone tumors. Cancer 91(3): 457–462

    Article  PubMed  CAS  Google Scholar 

  • Cox TM (2005) Substrate reduction therapy for lysosomal storage diseases. Acta Paediatr Suppl. 94(447): 69–75

    Article  PubMed  CAS  Google Scholar 

  • Cox TM (2001) Gaucher disease: understanding the molecular pathogenesis of sphingolipidoses. J Inherit Metab Dis 24[Suppl 2]: 106–121

    PubMed  CAS  Google Scholar 

  • Cox TM, JM Aerts, G Andria et al. (2003) The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (nonneuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis 26(6): 513–526

    Article  PubMed  CAS  Google Scholar 

  • Hollak CE, M Maas, JM Aerts (2001) Clinically relevant therapeutic endpoints in type I Gaucher disease. J Inherit Metab Dis 24[Suppl 2]: 97–105

    Article  PubMed  CAS  Google Scholar 

  • Mankin HJ, Rosenthal DI, Xavier R (2001) Gaucher disease. New approaches to an ancient disease. J Bone Joint Surg Am 83-a(5): 748–762

    PubMed  CAS  Google Scholar 

  • Niederau C (2004) Substrathemmung durch Miglustat. Neue Behandlungsstrategie der Gaucher-Krankheit. Arzneimittel-therapie 22(5): 136–141

    Google Scholar 

  • Niederau C, A Rolfs, S vom Dahl et al. (2001) Diagnosis and therapy of Gaucher disease. Current recommendations of German therapy centers in the year 2000. Med Klin 96(1): 32–39

    Article  CAS  Google Scholar 

  • Platt FM, M Jeyakumar, U Andersson et al. (2001) Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy. J Inherit Metab Dis 24(2): 275–290

    Article  PubMed  CAS  Google Scholar 

Literatur

  • Elliott MA, Pardanani A, Li CY et al. (2004) Immunophenotypic normalization of aberrant mast cells accompanies histological remission in imatinibtreated patients with eosinophiliaassociated mastocytosis. Leukemia 18(5): 1027–1029

    Article  PubMed  CAS  Google Scholar 

  • Hartmann K, Bruns SB, Henz BM (2001) Mastocytosis: review of clinical and experimental aspects. J Investig Dermatol Symp Proc 6(2): 143–147

    Article  PubMed  CAS  Google Scholar 

  • Horny HP, Valent P (2001) Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 25(7): 543–551

    Article  PubMed  CAS  Google Scholar 

  • Ludolph-Hauser D, Rueff F, Sommerhoff CP et al. (1999) Tryptase, a marker for the activation and localization of mast cells. Hautarzt 50(8): 556–561

    Article  PubMed  CAS  Google Scholar 

  • Marone G, Spadaro G, Granata F et al. (2001) Treatment of mastocytosis: pharmacologic basis and current concepts. Leuk Res 25(7): 583–594

    Article  PubMed  CAS  Google Scholar 

  • Pardanani A, Elliott M, Reeder T et al. (2003) Imatinib for systemic mastcell disease. Lancet 362(9383): 535–536

    Article  PubMed  CAS  Google Scholar 

  • Pardanani A, Ketterling RP, Brockman SR et al. (2003) CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 102(9): 3093–3096

    Article  PubMed  CAS  Google Scholar 

  • Pardanani A, Reeder T, Porrata LF et al. (2003) Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 101(9): 3391–3397

    Article  PubMed  CAS  Google Scholar 

  • Pardanani A, Tefferi A (2004) Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 104: 1931–1939

    Article  PubMed  CAS  Google Scholar 

  • Pardanani A, Tefferi A (2004) Imatinib therapy for hypereosinophilic syndrome and eosinophilia associated myeloproliferative disorders. Leuk Res 28[Suppl 1]: 47–52

    Article  Google Scholar 

  • Tefferi A, Pardanani A (2004) Clinical, genetic, and therapeutic insights into systemic mast cell disease. Curr Opin Hematol 11(1): 58–64

    Article  PubMed  Google Scholar 

  • Tefferi A, Pardanani A (2004) Systemic mastocytosis: current concepts and treatment advances. Curr Hematol Rep 3(3): 197–202

    PubMed  Google Scholar 

  • Valent P, Horny HP, Escribano L et al. (2001) Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 25(7): 603–625

    Article  PubMed  CAS  Google Scholar 

Literatur

  • Gadner H (1999) Langerhans’ cell histiocytosis — still an unsolved problem. Ped Hematol Oncol 16: 1–5

    Article  Google Scholar 

  • Minkov M, Grois N, Heitger A, Potschger U, Westermeier T, Gadner H (2000) Treatment of multisystem Langerhans cell histiocytosis. Results of DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group. Klin Padiatr 214(4): 139–144

    Article  Google Scholar 

  • Gadner H, Grois N, Arico M and the Histiocyte Society (2001) A randomised trial of treatment for multisystem Langerhans’ cell histiocytosis. J Pediatr 138(5): 728–734

    Article  PubMed  CAS  Google Scholar 

  • Histiocyte Society (2001) LCH-III, treatment protocol of the third international study for Langerhans cell histiocytosis.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik I für Innere Medizin, Universität zu Köln, Kerpener Straße 62, 50937, Köln

    PD Dr. Peter Staib

  2. Experimentelle Infektiologie Klinik I für Innere Medizin, Klinikum der Universität zu Köln, Kerpener Straße 62, 50937, Köln

    PD Dr. Pia Hartmann

  3. Experimentelle Infektiologie Klinik I für Innere Medizin, Klinikum der Universität zu Köln, Kerpener Straße 62, 50937, Köln

    PD Dr. Pia Hartmann

  4. Experimentelle Infektiologie Klinik I für Innere Medizin, Klinikum der Universität zu Köln, Kerpener Straße 62, 50937, Köln

    PD Dr. Pia Hartmann

  5. Experimentelle Infektiologie Klinik I für Innere Medizin, Klinikum der Universität zu Köln, Kerpener Straße 62, 50937, Köln

    PD Dr. Pia Hartmann

  6. Experimentelle Infektiologie Klinik I für Innere Medizin, Klinikum der Universität zu Köln, Kerpener Straße 62, 50937, Köln

    PD Dr Pia Hartmann

  7. Klinik I für Innere Medizin, Universität zu Köln, Kerpener Straße 62, 50937, Köln

    PD Dr. Peter Staib

Authors
  1. PD Dr. Peter Staib
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. PD Dr. Pia Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. PD Dr. Pia Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. PD Dr. Pia Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. PD Dr. Pia Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. PD Dr Pia Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. PD Dr. Peter Staib
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik für Innere Medizin I, Klinikum der Universität Regensburg, 93042, Regensburg

    Jürgen Schölmerich

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Staib, P. et al. (2007). Erkrankungen des granulozytären/ monozytären Systems. In: Schölmerich, J. (eds) Medizinische Therapie 2007 | 2008. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-48554-4_29

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-48554-4_29

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-48553-7

  • Online ISBN: 978-3-540-48554-4

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation